References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEvolution récente de l'incidence des fractures de hanche et de la consommation de médicaments anti-ostéoporotiques en Belgique
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Roberfroid, D. et al

in Revue du Rhumatisme (2011, December), 78(Suppl. 5), 43-44

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic implications of non-adherence with osteoporosis medications in Ireland
Hiligsmann, Mickaël ULg; McGowan, Bernie; Bennett, Kathleen et al

Conference (2011, November)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailTumor-induced osteomalacia: The tumor may stay hidden!
van der Rest, Catherine; CAVALIER, Etienne ULg; KAUX, Jean-François ULg et al

in Clinical Biochemistry (2011), 44(14-15), 1264-6

We report the case of a patient with severe muscular and articular tenderness that caused almost complete immobility. This subject had severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth ... [more ▼]

We report the case of a patient with severe muscular and articular tenderness that caused almost complete immobility. This subject had severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth factor 23 (FGF-23) was abnormally high and the diagnostic of tumor-induced osteomalacia was made. Despite multiple tests, the tumor was not localized. In this report, we discuss different possible investigations to localize the tumor. Lastly, we review the potential therapy available when tumor is not found and can thus not be excised. [less ▲]

Detailed reference viewed: 48 (17 ULg)
Full Text
Peer Reviewed
See detailHypophosphatémie et ostéomalacie oncogénique
Van der Rest, Catherine; CAVALIER, Etienne ULg; COLSON, Laurent ULg et al

in Revue Médicale Suisse (2011), 7

In this article, we will discuss about hypophosphatemia due to tumor-induced osteomalacia. This disease is characterized by severe muscular and articular tenderness inducing profound walking limitation ... [more ▼]

In this article, we will discuss about hypophosphatemia due to tumor-induced osteomalacia. This disease is characterized by severe muscular and articular tenderness inducing profound walking limitation. Clinical chemistry results show severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth factor 23 (FGG-23) is abnormally high. Physiological role of FGF-23 is examined. We also consider the pathophysiology of tumor induced osteomalacia, the use of different investigations to localize the tumor and therapies available to treat this rare disease. [less ▲]

Detailed reference viewed: 94 (8 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickaël ULg; Reginster, Jean-Yves ULg

in Osteoporosis International (2011, March), 22(Suppl.1), 112-113

Detailed reference viewed: 44 (11 ULg)
Full Text
Peer Reviewed
See detailLong-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years
Reginster, Jean-Yves ULg; Kaufman, Jean-Marc; Devogelaer, Jean-Pierre et al

in Osteoporosis International (2011, March), 22(Suppl.1), 110-111

Detailed reference viewed: 38 (6 ULg)
Full Text
Peer Reviewed
See detailHospitalisation costs of hip fractures in Belgium
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 332

Detailed reference viewed: 33 (7 ULg)
Full Text
Peer Reviewed
See detailPatient out-of-pocket contributions related to hip fracture hospital costs in Belgium
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 333

Detailed reference viewed: 46 (23 ULg)
Full Text
Peer Reviewed
See detailProtecting men and women from fracture
Reginster, Jean-Yves ULg

in Osteoporosis International (2011, March), 22(Suppl.1), 413-414

Detailed reference viewed: 26 (5 ULg)
Full Text
Peer Reviewed
See detailThe true clinical relevance of crystalline glucosamine sulphate in the treatment of knee osteoarthritis
Reginster, Jean-Yves ULg

in Osteoporosis International (2011, March), 22(Suppl.1), 410

Detailed reference viewed: 105 (4 ULg)
Full Text
Peer Reviewed
See detailAntifracture efficacy and safety of once-yearly Zoledronic acid 5mg in men with osteoporosis: a prospective, randomized, controlled trial
Boonen, Steven; Su, Guoqin; Incera, Elodie et al

in Osteoporosis International (2011, March), 22(Suppl.1), 112

Detailed reference viewed: 58 (1 ULg)
Full Text
Peer Reviewed
See detailFive-year Denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the freedom trial extension
Papapoulos, S.; Man, Z.; Mellstrom, D. et al

in Osteoporosis International (2011, March), 22(Suppl.1), 107-108

Detailed reference viewed: 98 (6 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate increases cell viability in IL-1 beta stimulated human chondrocytes
Merville, Marie-Paule ULg; Deroyer, Céline ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 53-54384

Detailed reference viewed: 41 (22 ULg)
Full Text
Peer Reviewed
See detailRisk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study
Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg; Zegels, Brigitte ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 332-333

Detailed reference viewed: 22 (7 ULg)